MGUS: Risk of Progression to Multiple Myeloma Can Change Over Time
A risk signature is not constant in a given patient over time—it is subject to change depending on a variety of factors.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.” -
T-Cell Cryopreservation for Use in Future Cancer Treatment: Hot or Hype?
Can healthy immune cells from a patient be frozen and used in the future to make adoptive cell therapies in the event of a cancer diagnosis? -
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported. -
A BCMA-Targeted BiTE in Multiple Myeloma: It’s Not Just One BiTE
A bispecific T-cell engager that targets B-cell maturation antigen generated high response rates in multiple myeloma — but so have other BCMA-targeted agents.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Androgen Therapy in Lower-Risk Myelodysplastic Syndrome Can Result in Hematologic Improvement
Patient Preferences Explored in Multiple Myeloma Treatment
Tumor-Initiating Cell Marker Identified in Myeloma
New Treatment Option Approved for Patients With Myelofibrosis
Cost Burden of Disease Progression High in Multiple Myeloma
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
